Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Prospective studies are needed to validate the safety and cost-effectiveness of individualized warfarin dosing models incorporating genetic and clinical factors.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Prontera et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: